Cancer Targeted Technology (CTT) develops innovative targeted agents for cancer that accurately detect, stratify and treat early and advanced disease, and monitor treatment efficacy to improve patient survival and quality of life.
CTT is a biotechnology company commercializing innovative small molecules that bind pivotal enzyme targets in cancer. CTT has rationally designed and patented a targeting scaffold that recognizes the molecular target, Prostate-Specific Membrane Antigen (PSMA), with unparalleled binding characteristics, making it stand out from its competitors. PSMA is an exceptional biomarker, expressed on close to 90% of prostate tumors, with increased PSMA expression correlated with disease progression while normal tissue expression of PSMA is negative to low. CTT’s small molecule drugs are unique as they bind irreversibly to the PSMA target and are rapidly internalized by PSMA-expressing tumor cells. As a consequence of this, more of the drug reaches and stays at the tumor site. CTT’s targeting agents act as a platform to effectively and safely deliver a wide variety of diagnostic and therapeutic payloads.
CTT’s is initially targeting prostate cancer with these drugs. More than 2.9 million men in the US suffer from prostate cancer with approximately 200,000 new cases and approximately 30,000 men expected to die from the disease per year. PSMA is also expressed on the new blood vessels of other solid tumors, including colon, liver, renal cell, and lung, providing a broad market for CTT’s PSMA-targeted agents.
CTT’s unique cancer agents are designed to accurately detect, stratify and treat early and advanced disease, monitor treatment efficacy and improve patient survival and quality of life.